Pathology Imaging Systems Market Global Report 2026

The pathology imaging systems market size has grown rapidly in recent years. It will grow from $1.37 billion in 2025 to $1.52 billion in 2026 at a compound annual growth rate (CAGR) of 10.7%. The growth in the historic period can be attributed to reliance on manual microscopy processes, limited adoption of digital pathology solutions, high costs associated with imaging scanner systems, shortage of qualified pathologists, and insufficient data storage infrastructure.

The pathology imaging systems market size is expected to see rapid growth in the next few years. It will grow to $2.3 billion in 2030 at a compound annual growth rate (CAGR) of 10.9%. The growth in the forecast period can be attributed to the adoption of AI-assisted diagnostic systems, expansion of cloud-based pathology platforms, rising demand for precision medicine approaches, growth in remote diagnostic and telepathology services, and integration of hospital IT systems with imaging ecosystems. Major trends in the forecast period include increasing adoption of telepathology and remote diagnostic outsourcing models, rising demand for whole-slide imaging standardization and interoperability, expansion of centralized pathology laboratories across multi-hospital networks, growing regulatory focus on digital pathology validation and diagnostic accuracy standards, and increased integration of laboratory information systems with imaging workflows.

The expansion of clinical trial activities is expected to propel the growth of the pathology imaging systems market going forward. Clinical trial activities refer to the structured process of conducting research studies involving human participants to assess the safety and effectiveness of new drugs, therapies, medical devices, and diagnostic tools. The rising volume of clinical trials is primarily driven by increased pharmaceutical and biotechnology research and development investments, as companies along with government bodies accelerate efforts to discover new treatments across a broad spectrum of diseases. This increase in clinical trial activity strengthens demand for pathology imaging systems, as these systems play a vital role in accurate tissue examination, biomarker detection, and real-time tracking of patient outcomes within research environments. For instance, in December 2024, according to the Association of the British Pharmaceutical Industry, a UK-based trade association, the number of pharmaceutical industry trials initiated in the UK rose for the second consecutive year, increasing from 411 in 2022 to 426 in 2023. Therefore, the expansion of clinical trial activities is driving the growth of the pathology imaging systems market.

Key companies operating in the pathology imaging systems market are focusing on developing advanced solutions, such as AI-powered quality control software, to enhance image consistency, reduce manual intervention, and improve laboratory workflow efficiency. AI-powered quality control software refers to intelligent imaging technology that automatically detects scanning artifacts and image quality issues during slide digitization, helping laboratories minimize rework and improve diagnostic precision. For example, in March 2026, Leica Biosystems, a US-based provider of anatomic and digital pathology solutions, launched the Aperio GT Elite scanner along with Aperio iQC software. The solution integrates AI-powered quality control directly into the digital pathology workflow, enabling automatic detection of whole-slide imaging artifacts while slides remain on the scanner. The system offers high-throughput slide processing, barcode-driven automation, and faster quality control review, supporting improved laboratory efficiency, workflow standardization, and enhanced pathology imaging performance.

In June 2024, Quest Diagnostics, a US-based provider of diagnostic information services and laboratory testing solutions, acquired the laboratory assets of PathAI Diagnostics from PathAI for an undisclosed amount. Through this acquisition, Quest Diagnostics seeks to speed up the implementation of artificial intelligence and digital pathology technologies in order to improve cancer diagnosis and enhance diagnostic efficiency across its pathology network. PathAI is a US-based company offering AI-powered digital pathology solutions, including advanced imaging capabilities, data analytics, and diagnostic support services for pathology laboratories and biopharmaceutical organizations.

Major companies operating in the pathology imaging systems market are F. Hoffmann-La Roche AG, FUJIFILM Corporation, Philips Healthcare, GE HealthCare Technologies Inc., Agilent Technologies Inc., Olympus Corporation, Carl Zeiss Meditec AG, Hamamatsu Photonics K.K., Huron Technologies International Inc., Leica Biosystems Nussloch GmbH, Motic Xiamen Medical Diagnostic Systems Co. Ltd., Sectra AB, Sakura Finetek Japan Co. Ltd., Akoya Biosciences Inc., OptraSCAN Inc., Visiopharm A/S, Indica Labs LLC, SPOT Imaging, Objective Imaging Ltd., Corista LLC, Glencoe Software Inc., Paige.ai, PathAI, Proscia, Ibex Medical Analytics, Tribun Health.

North America was the dominant region in the pathology imaging systems market in 2025. Asia-Pacific is expected to be the rapidly expanding regionin the forecast period. The regions covered in the pathology imaging systems market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the pathology imaging systems market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The pathology imaging systems market consists of revenues earned by entities by providing services such as digital pathology services, image analysis services, cloud-based pathology data management services, telepathology services, system integration services, and consulting services. The market value includes the value of related goods sold by the service provider or included within the service offering. The pathology imaging systems market also includes sales of slide scanners, digital microscopes, AI-based diagnostic tools, storage systems, servers, display systems, and laboratory information systems (LIS) integration tools. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

The pathology imaging systems market research report is one of a series of new reports that provides pathology imaging systems market statistics, including pathology imaging systems industry global market size, regional shares, competitors with a pathology imaging systems market share, detailed pathology imaging systems market segments, market trends and opportunities, and any further data you may need to thrive in the pathology imaging systems industry. This pathology imaging systems market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

This product will be delivered within 1-3 business days.